Enfusion, Inc. (NYSE:ENFN - Get Free Report) General Counsel Matthew Campobasso sold 1,695 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $19,289.10. Following the completion of the transaction, the general counsel now directly owns 70,946 shares of the company's stock, valued at $807,365.48. The trade was a 2.33 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Matthew Campobasso also recently made the following trade(s):
- On Monday, March 3rd, Matthew Campobasso sold 1,081 shares of Enfusion stock. The stock was sold at an average price of $11.48, for a total value of $12,409.88.
- On Tuesday, January 7th, Matthew Campobasso sold 976 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total value of $9,886.88.
Enfusion Stock Performance
ENFN stock opened at $11.24 on Friday. Enfusion, Inc. has a one year low of $7.83 and a one year high of $11.80. The firm has a market cap of $1.44 billion, a PE ratio of 280.95, a PEG ratio of 1.85 and a beta of 0.95. The firm's 50 day moving average price is $10.98 and its 200-day moving average price is $9.88.
Enfusion (NYSE:ENFN - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The business had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Equities research analysts predict that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have commented on ENFN. Stifel Nicolaus increased their target price on Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. William Blair restated a "market perform" rating on shares of Enfusion in a report on Monday, January 13th. Finally, Piper Sandler lifted their price target on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a report on Monday, December 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $11.13.
Read Our Latest Stock Report on ENFN
Institutional Trading of Enfusion
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Azora Capital LP boosted its position in shares of Enfusion by 3,255.9% during the 4th quarter. Azora Capital LP now owns 1,000,967 shares of the company's stock worth $10,310,000 after purchasing an additional 971,140 shares during the period. Silvercrest Asset Management Group LLC purchased a new stake in Enfusion during the fourth quarter worth about $4,300,000. TenCore Partners LP acquired a new stake in shares of Enfusion during the third quarter worth about $3,938,000. EVR Research LP purchased a new position in shares of Enfusion in the fourth quarter valued at approximately $4,120,000. Finally, New York State Common Retirement Fund grew its holdings in shares of Enfusion by 23.8% in the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company's stock valued at $19,848,000 after purchasing an additional 370,498 shares in the last quarter. 81.05% of the stock is currently owned by hedge funds and other institutional investors.
About Enfusion
(
Get Free Report)
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
